Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

GSK Investigational Site, Orbassano (TO)

GSK Investigational Site, Gyeonggi-do

GSK Investigational Site, Seongnam

GSK Investigational Site, Caen

GSK Investigational Site, Berlin

GSK Investigational Site, Milan

GSK Investigational Site, Großhansdorf

GSK Investigational Site, Madrid

GSK Investigational Site, Madrid

GSK Investigational Site, Cheongju-si

GSK Investigational Site, Bordeaux

GSK Investigational Site, Immenhausen

GSK Investigational Site, Nashville

GSK Investigational Site, Santander

GSK Investigational Site, Seville

GSK Investigational Site, Nantes

GSK Investigational Site, Meldola (FC)

GSK Investigational Site, Ravenna

GSK Investigational Site, Paris

GSK Investigational Site, Dallas

GSK Investigational Site, Paris

GSK Investigational Site, Villejuif

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Craiova

GSK Investigational Site, Timișoara

GSK Investigational Site, Floreşti

GSK Investigational Site, Chelyabinsk

GSK Investigational Site, St Louis

GSK Investigational Site, Toronto

GSK Investigational Site, Gauting

GSK Investigational Site, Leipzig

GSK Investigational Site, Madrid

GSK Investigational Site, Maastricht

GSK Investigational Site, Lodz

GSK Investigational Site, Poznan

GSK Investigational Site, Warsaw

GSK Investigational Site, Bucharest

GSK Investigational Site, Otopeni

GSK Investigational Site, Seoul

GSK Investigational Site, Barcelona

GSK Investigational Site, Barcelona

GSK Investigational Site, Uppsala